MARINUS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Marinus Pharmaceuticals, Inc. - MRNS
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 06 2025
0mins
Should l Buy ?
Source: Businesswire
Investigation into Marinus Pharmaceuticals Sale: Former Louisiana Attorney General Charles C. Foti, Jr. and Kahn Swick & Foti, LLC are investigating the proposed sale of Marinus Pharmaceuticals to Immedica Pharma AB, where shareholders would receive $0.55 per share, to assess if this offer undervalues the company.
Legal Rights and Contact Information: KSF is inviting shareholders who believe the transaction undervalues Marinus or wish to discuss their legal rights to contact them without obligation, emphasizing the urgency due to the tender offer structure of the transaction.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
